Story perspectives

Supreme Court, Study Retraction, Chemo Shortage Undermine Cancer Care

6/26/2026

Summary

Story summary

The U.S. Supreme Court ruled 7-2 that federal pesticide rules preempt state lawsuits, overturning a $1.25 million verdict against Roundup’s maker.
Nature Medicine retracted a Chinese study that said morning immunotherapy doubled lung-cancer survival after design flaws were found.
U.S. doctors report shortages of cheap generic chemotherapy, forcing prioritization of younger patients.
Patients and advocates warn that drug scarcity, corporate legal shields, and flawed research together jeopardize fair cancer care.

1 of 1

Story summary

The U.S. Supreme Court ruled 7-2 that federal pesticide rules preempt state lawsuits, overturning a $1.25 million verdict against Roundup’s maker.
Nature Medicine retracted a Chinese study that said morning immunotherapy doubled lung-cancer survival after design flaws were found.
U.S. doctors report shortages of cheap generic chemotherapy, forcing prioritization of younger patients.
Patients and advocates warn that drug scarcity, corporate legal shields, and flawed research together jeopardize fair cancer care.